Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016

  • ID: 3802767
  • Drug Pipelines
  • 49 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amura Holdings Limited
  • Medivir AB
  • Merck & Co., Inc.
  • Virobay Inc.
  • MORE
Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016

Summary

‘Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016’, provides in depth analysis on Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted pipeline therapeutics.

The report provides comprehensive information on the Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38)
- The report reviews Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amura Holdings Limited
  • Medivir AB
  • Merck & Co., Inc.
  • Virobay Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Overview

Therapeutics Development

Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Products under Development by Stage of Development

Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Products under Development by Therapy Area

Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Products under Development by Indication

Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Products under Development by Companies

Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Companies Involved in Therapeutics Development

Amura Holdings Limited

Medivir AB

Merck & Co., Inc.

Virobay Inc.

Wroclawskie Centrum Badan EIT+ Sp. z o.o.

Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Drug Profiles

AM-3701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-3876 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MIV-711 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

odanacatib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CTSK for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBY-129 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBY-285 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Dormant Projects

Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Discontinued Products

Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Featured News & Press Releases

Jan 28, 2016: Medivir initiates phase IIa study of MIV-711 in knee osteoarthritis

Sep 15, 2014: Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis

Oct 09, 2013: Medivir: Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders

May 21, 2013: Medivir Presents Positive Results From Phase Ia Study With MIV-711 For Treatment Of Skeletal Disorders At 2013 ECTS Annual Meeting

Oct 13, 2012: Merck Announces Results From Phase II Clinical Trial Of Odanacatib In Post-Menopausal Osteoporosis

Aug 21, 2012: Medivir Commences Phase Ib Trial Of MIV-711 For Treatment Of Skeletal Disorders

Jul 11, 2012: Merck Provides Update On Phase III Trial Of Odanacatib For Treatment Of Osteoporosis

May 28, 2012: Medivir Initiates Phase I Clinical Trial Of MIV-711 For Treatment Of Bone Disorders

Mar 19, 2012: Medivir To File Application For Initiation Of Phase I Trials Of MIV-711

Sep 19, 2011: Merck Announces Presentation Of New Data On Odanacatib Phase III Investigational Cat-K Inhibitor For Osteoporosis At Annual Meeting Of American Society For Bone And Mineral Research

Oct 18, 2010: Merck Presents New Data On Odanacatib For Treatment of Osteoporosis In Postmenopausal Women at ASBMR Annual Meeting

Sep 16, 2009: Medivir Presented Its Cathepsin K Program at the Ongoing 31st Asbmr Meeting in Denver, USA

Sep 14, 2009: New, Long-Term Data For Odanacatib, Merck's Investigational Cat K Inhibitor, Showed Positive Results In Treating Osteoporosis

Sep 01, 2009: Medivir Broadens Its Bone Disease Portfolio By Designating One Further Candidate Drug (CD), MIV-711

Sep 16, 2008: Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Increased Bone Mineral Density (BMD) Over Two Years At Key Fracture Sites In Phase IIB Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 49List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Amura Holdings Limited, H1 2016

Pipeline by Medivir AB, H1 2016

Pipeline by Merck & Co., Inc., H1 2016

Pipeline by Virobay Inc., H1 2016

Pipeline by Wroclawskie Centrum Badan EIT+ Sp. z o.o., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016 34List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Amura Holdings Limited
  • Medivir AB
  • Merck & Co., Inc.
  • Virobay Inc.
  • MORE
Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Cathepsin K or CTSK is an enzyme encoded by CTSK gene. It is closely involved in osteoclastic bone resorption and participates partially in the disorder of bone remodeling. It plays an important role in extracellular matrix degradation. The enzyme is ability to catabolize elastin, collagen, and gelatin allow it to break down bone and cartilage.

Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies.The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 3 and 1 respectively.

The author's latest report Cathepsin K - Pipeline Review, H1 2016, outlays comprehensive information on the Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
Amura Holdings Limited
Medivir AB
Merck & Co., Inc.
Virobay Inc.
Wroclawskie Centrum Badan EIT+ Sp. z o.o.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll